Arm 1: Alisertib
death, neutropenia, leukopenia, anemia, PD
LEUKOPENIA, NEUTROPENIA, ANEMIA
Three of 46 patients continued to receive alisertib as of the data lock. Reasons for discontinuing treatment included PD (38 [82.6%]), intolerability (2 [4.3%]), death (2 [4.3%]), and physician decision (1 [2.2%]). The median treatment cycles completed was 6 (range, 1-34). Seventeen patients (37.0%) required at least 1 dose reduction during the first year, most commonly due to neutropenia and anemia. The most common grade 3 or higher toxic effects were neutropenia (20 [43.4%]), leukopenia (8 [17.4%]), and anemia (9 [19.6%]). 